Investor directory

Quantum Pacific Capital

Quantum Pacific Capital Ltd. is a private equity firm that specializes in acquiring, owning, operating, and managing businesses in various sectors, including natural resources, power and infrastructure, media, and telecommunications. The firm focuses on both greenfield and brownfield investments in power and infrastructure, seeking opportunities with shorter payback periods and minimal reliance on government support. In the telecommunications sector, Quantum Pacific targets investments in mobile and wireless technologies across the ASEAN region. Primarily active in Asia, Australia, and North America, the firm has its headquarters in Central, Hong Kong, and maintains partner offices in Singapore, Vancouver, and Los Angeles.
http://www.quantumpacificcapital.com
https://crunchbase.com/organization/quantum-pacific-capital
https://facebook.com/157521087633340
https://linkedin.com/company/quantum-pacific-capital-ltd
https://pitchbook.com/profiles/investor/52141-42
https://twitter.com/gcmazur
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=131003942

Idan Ofer

Principal

2 past transactions

EkWateur

Series B in 2022
EkWateur, founded in November 2015, aims to become a significant player in the French energy retail market by offering a seamless and innovative customer experience. The company specializes in supplying 100% green energy, including electricity, gas, and firewood, to both residential and business clients. By providing a user-friendly platform, EkWateur enables customers to easily switch to more transparent and environmentally friendly energy sources. This approach not only supports individual energy transitions but also encourages large producers to move away from fossil fuels, thereby promoting a cleaner energy future.

Indel Therapeutics

Series B in 2011
Indel Therapeutics Inc. is a Vancouver‐based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult‐to‐treat and hospital‐acquired infections. These programs are based on Indel's paradigm‐changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.